Thiopurine methyltransferase activity in Spain: A study of 14,545 patients

Digestive Diseases and Sciences

Volumn 52, Issue 5, 2007, Pages 1262-1269

  Gisbert, Javier P ^a   Gomollón, Fernando ^b   Cara, Carlos ^c   Luna, Marta ^a   González Lama, Yago ^a   Pajares, José María ^a   Maté, José ^a   Guijarro, Luis G ^d  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^c UCB PHARMA   (Belgium)

^d UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

6 Mercaptopurine; Autoimmune hepatitis; Azathioprine; Inflammatory bowel disease; Multiple sclerosis; Myasthenia gravis; Pemphigus; Thiopurine methyltransferase; TPMT

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; MESALAZINE; STEROID; THIOPURINE METHYLTRANSFERASE;

ADULT; ARTICLE; AUTOIMMUNE HEPATITIS; ENTERITIS; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; HEMATOCRIT; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; PEMPHIGUS; PRIORITY JOURNAL; SEX DIFFERENCE; SPAIN;

6-MERCAPTOPURINE; ADULT; AUTOIMMUNE DISEASES; AZATHIOPRINE; BONE MARROW DISEASES; ERYTHROCYTES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LINEAR MODELS; MALE; METHYLTRANSFERASES; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; SPAIN;

EID: 34247213437     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9119-z     Document Type: Article

References (40)

1. Czaja, AJ (2002) Treatment of autoimmune hepatitis. Semin Liver Dis 22:365-378
2. Sandborn, W, Sutherland, L, Pearson, D, May, G, Modigliani, R, Prantera, C (2000) Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane, Database Syst, Rev CD000545
3. Pearson, DC, May, GR, Fick, G, Sutherland, LR (2000) Azathioprine for maintaining remission of Crohn's disease. Cochrane, Database Syst, Rev CD000067
4. Fernandez, O, Fernandez, V, DeRamon, E (2004) Azathioprine and methotrexate in multiple sclerosis. J Neurol Sci 223:29-34
5. Gisbert, JP, Gomollon, F, Mate, J, Pajares, JM (2002) Individualized therapy with azathioprine or 6-mercaptopurine by monitoring thiopurine methyl-transferase (TPMT) activity. Rev Clin Esp 202:555-562
6. Tidd, DM, Paterson, AR (1974) A biochemical mechanism for the delayed cytotoxic reaction of 6- mercaptopurine. Cancer Res 34:738-746
7. Lennard, L, VanLoon, JA, Weinshilboum, RM (1989) Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 46:149-154
8. Dubinsky, MC, Lamothe, S, Yang, HY, Targan, SR, Sinnett, D, Theoret, Y, et al (2000) Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118:705-713
9. Anstey, A, Lennard, L, Mayou, SC, Kirby, JD: Pancytopenia related to azathioprine - an enzyme deficiency caused by a common genetic polymorphism (1992) a review. J R Soc Med 85:752-756
10. Lowry, PW, Franklin, CL, Weaver, AL, Gennett Pike, M, Mays, DC, Tremaine, WJ, et al. (2001) Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 49:665-670
11. Lennard, L (1999) Therapeutic drug monitoring of antimetabolic cytotoxic drugs. Br J Clin Pharmacol 47:131-143
12. Weinshilboum, RM, Sladek, SL (1980) Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32:651-662
13. Menor, C, Fueyo, J, Escribano, O, Pina, MJ, Redondo, P, Cara, C, et al. (2002) Thiopurine methyltransferase activity in a Spanish population sample: decrease of enzymatic activity in multiple sclerosis patients. Mult Scler 8:243-248
14. Decaux, G, Horsmans, Y, Houssiau, F, Desager, JP (2001) High 6-thioguanine nucleotide levels and low thiopurine methyltransferase activity in patients with lupus erythematosus treated with azathioprine. Am J Ther 8:147-150
15. Menor, C, Fueyo, JA, Escribano, O, Cara, C, Fernandez-Moreno, MD, Roman, ID, et al. (2001) Determination of thiopurine methyltransferase activity in human erythrocytes by high-performance liquid chromatography: comparison with the radiochemical method. Ther Drug Monit 23:536-541
16. Snow, JL, Gibson, LE (1995) The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 131:193-197
17. Lowenthal, A, Meyerstein, N, Ben-Zvi, Z (2001) Thiopurine methyltransferase activity in the Jewish population of Israel. Eur J Clin Pharmacol 57:43-46
18. Spire-Vayron de la Moureyre, C, Debuysere, H, Mastain, B, Vinner, E, Marez, D, Lo Guidice, JM, et al. (1998) Genotypic and phenotypic analysis of the polymorphic thiopurine S- methyltransferase gene (TPMT) in a European population. Br J Pharmacol 125:879-887
19. Park-Hah, JO, Klemetsdal, B, Lysaa, R, Choi, KH, Aarbakke, J (1996) Thiopurine methyltransferase activity in a Korean population sample of children. Clin Pharmacol Ther 60:68-74
20. Kroplin, T, Weyer, N, Gutsche, S, Iven, H (1998) Thiopurine S-methyltransferase activity in human erythrocytes: a new HPLC method using 6-thioguanine as substrate. Eur J Clin Pharmacol 54:265-271
21. Szumlanski, CL, Honchel, R, Scott, MC, Weinshilboum, RM (1992) Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics 2:148-159
22. Campbell, S, Kingstone, K, Ghosh, S (2002) Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine. Aliment Pharmacol Ther 16:389-398
23. Gisbert, JP, Luna, M, Mate, J, Gonzalez-Guijarro, L, Cara, C, Pajares, JM (2003) Thiopurine methyltransferase activity and myelosuppression in inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Med Clin (Barc) 121:1-5
24. Mircheva, J, Legendre, C, Soria-Royer, C, Thervet, E, Beaune, P, Kreis, H (1995) Monitoring of azathioprine-induced immunosuppression with thiopurine methyltransferase activity in kidney transplant recipients. Transplantation 60:639-642
25. Thervet, E, Anglicheau, D, Toledano, N, Houllier, AM, Noel, LH, Kreis, H, et al. (2001) Long-term results of TMPT activity monitoring in azathioprine-treated renal allograft recipients. J Am Soc Nephrol 12:170-176
26. Weyer, N, Kroplin, T, Fricke, L, Iven, H (2001) Human thiopurine S-methyltransferase activity in uremia and after renal transplantation. Eur J Clin Pharmacol 57:129-136
27. Chocair, PR, Duley, JA, Simmonds, HA, Cameron, JS (1992) The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 53:1051-1056
28. Schutz, E, Gummert, J, Mohr, FW, Armstrong, VW, Oellerich, M (1995) Azathioprine myelotoxicity related to elevated 6-thioguanine nucleotides in heart transplantation. Transplant Proc 27:1298-1300
29. Lennard, L, Van Loon, JA, Lilleyman, JS, Weinshilboum, RM (1987) Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 41:18-25
30. Lennard, L, Lilleyman, JS, Van Loon, J, Weinshilboum, RM (1990) Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336:225-229
31. McLeod, HL, Relling, MV, Liu, Q, Pui, CH, Evans, WE (1995) Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 85:1897-1902
32. Keuzenkamp-Jansen, CW, Leegwater, PA, De Abreu, RA, Lambooy, MA, Bokkerink, JP, Trijbels, JM (1996) Thiopurine methyltransferase: a review and a clinical pilot study. J Chromatogr B Biomed Appl 678:15-22
33. Szumlanski, CL, Weinshilboum, RM (1995) Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interactionwith 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 39:456-459
34. Lewis, LD, Benin, A, Szumlanski, CL, Otterness, DM, Lennard, L, Weinshilboum, RM, et al. (1997) Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther 62:464-475
35. Lowry, PW, Franklin, CL, Weaver, AL, Szumlanski, CL, Mays, DC, Loftus, EV, et al. (2001) Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 49:656-664
36. Lowry, PW, Szumlanski, CL, Weinshilboum, RM, Sandborn, WJ (1999) Balsalazide and azathioprine or 6-mercaptopurine: evidence for a potentially serious drug interaction. Gastroenterology 116:1505-1506
37. Campbell, S, Ghosh, S (2001) Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy. Eur J Gastroenterol Hepatol 13:1297-1301
38. Dubinsky, MC, Yang, H, Hassard, PV, Seidman, EG, Kam, LY, Abreu, MT, et al. (2002) 6-MP metabolite profiles provide abiochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 122:904-915
39. Winter, J, Walker, A, Shapiro, D, Gaffney, D, Spooner, RJ, Mills, PR (2004) Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 20:593-599
40. Dubinsky, MC, Reyes, E, Ofman, J, Chiou, CF, Wade, S, Sandborn, WJ (2005) A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol 100:2239-2247